Revance Therapeutics Releases Third Quarter 2014 Results
November 12, 2014 16:01 ET
|
Revance Therapeutics, Inc
– Confirmation of Plans to Initiate Phase 2 Active Comparator Study for RT002 in 2014 –
– Updated Full Year 2014 Financial Guidance –
NEWARK, Calif., Nov. 12, 2014 (GLOBE...
Revance Therapeutics, Inc. Announces Participation in Credit Suisse 2014 Healthcare Conference
November 04, 2014 16:10 ET
|
Revance Therapeutics, Inc
NEWARK, Calif., Nov. 4, 2014 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), a biopharmaceutical company developing botulinum toxin products for use in aesthetic and therapeutic...
Revance Therapeutics to Release Third Quarter 2014 Financial Results and Host Conference Call on Wednesday, November 12, 2014
October 29, 2014 16:01 ET
|
Revance Therapeutics, Inc
NEWARK, Calif., Oct. 29, 2014 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), a biopharmaceutical company developing botulinum toxin products for use in aesthetic and therapeutic...
Revance Therapeutics Provides Update on RT001 Clinical Program for the Lead Indication for Crow's Feet Lines
October 01, 2014 16:01 ET
|
Revance Therapeutics, Inc
NEWARK, Calif., Oct. 1, 2014 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), a biopharmaceutical company developing botulinum toxin products for use in aesthetic and therapeutic...
Revance Therapeutics Announces the Appointment of Azita Nejad as Vice President of Quality
September 22, 2014 16:10 ET
|
Revance Therapeutics, Inc
NEWARK, Calif., Sept. 22, 2014 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), a biopharmaceutical company developing botulinum toxin products for use in aesthetic and therapeutic...
Revance Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
September 02, 2014 16:10 ET
|
Revance Therapeutics, Inc
NEWARK, Calif., Sept. 2, 2014 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), a biopharmaceutical company developing botulinum toxin products for use in aesthetic and therapeutic...
Revance Therapeutics Releases Second Quarter 2014 Financial Results
August 12, 2014 16:10 ET
|
Revance Therapeutics, Inc
NEWARK, Calif., Aug. 12, 2014 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), a biopharmaceutical company developing botulinum toxin products for use in aesthetic and therapeutic...
Revance Therapeutics Appoints Industry Veteran Arthur P. Bertolino, M.D., Ph.D., M.B.A. as Chief Medical Officer
August 12, 2014 16:01 ET
|
Revance Therapeutics, Inc
NEWARK, Calif., Aug. 12, 2014 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), a biopharmaceutical company developing botulinum toxin products for use in aesthetic and therapeutic...
Revance Therapeutics to Release Second Quarter 2014 Financial Results and Host Conference Call on Tuesday, August 12, 2014
July 29, 2014 16:02 ET
|
Revance Therapeutics, Inc
NEWARK, Calif., July 29, 2014 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), a biopharmaceutical company developing botulinum toxin products for use in aesthetic and therapeutic...
Revance Therapeutics Announces Closing of Its Follow-on Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
June 24, 2014 16:05 ET
|
Revance Therapeutics, Inc
NEWARK, Calif., June 24, 2014 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), a biopharmaceutical company developing botulinum toxin products for use in aesthetic and therapeutic...